期刊
CANCER CELL
卷 25, 期 1, 页码 102-117出版社
CELL PRESS
DOI: 10.1016/j.ccr.2013.12.010
关键词
-
资金
- National Research Foundation of Korea
- Ministry of Science, ICT, and Future Planning [NRF-2009-0079390, NRF-2013M3A9B6046565, NRF-2012M3A9C 4048758]
- Ministry of Health and Welfare [A110076]
- JSPS KAKENHI [25293078]
- Takeda Science Foundation
- Korea Health Promotion Institute [HI11C0069010013] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2013M3A9B6046565, 2009-0079390, KIB01, 2012M3A9C4048758] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- Grants-in-Aid for Scientific Research [25293078] Funding Source: KAKEN
Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects. To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression. RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure Of tumor vasculatures. Moreover, enhanced anticancer effects were observed when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent. These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据